Stephen Scelsa, MD Email Stephen Scelsa
- PROFESSOR | Neurology
- Electrodiagnostic Medicine
- Hospital Affiliations
- The Mount Sinai Hospital
- Mount Sinai Brooklyn
- Mount Sinai Morningside and Mount Sinai West
- Mount Sinai Beth Israel
- Mount Sinai Union Square 212-844-8490 212-844-8490
Book an Appointment - Stephen Scelsa
I am a neurologist and neuromuscular specialist with expertise in Amyotrophic Lateral Sclerosis (ALS) clinical care and trials. I am the co-founder and Director of the Beth Israel Medical Center/ALS Association NY Chapter ALS Center that was created in 1997. Since 2003, the center has gained national recognition for participation in ALS clinical trials. I have access to a large population of patients with Amyotrophic Lateral Sclerosis. We became part of the Mount Sinai Health System in 2013. We follow 120 patients at any given time. I am an active member of NEALS, the North Eastern ALS Consortium. I have a strong interest in conducting clinical trials in ALS and other neuromuscular diseases.
At Mount Sinai Beth Israel, we conducted an investigator initiated phase1/2 trial of indinavir in ALS, in collaboration with Columbia University Medical Center. I was the principle investigator.
Our center has also conducted a controlled study of reverse transcriptase detection in the serum and CSF of HIV negative, sporadic ALS patients.
I received 4 NIH consortium grants for clinical trials in ALS patients. The most recent was a phase 3 clinical trial of ceftriaxone in ALS, sponsored by Massachusetts General Medical Center and the NIH.
We are also participating in a new study to validate a new functional scale for PLS (primary lateral sclerosis) with Dr Mitsumoto at Columbia University. PLS is a neglected disease in clinical trials. I am very interested in developing new clinical trials in PLS and this project provides a great opportunity.
We conducted multiple clinical trials as a multi-site PI in NIH consortium grants, have participated in the first round of NeuroNext with our prior academic affiliation (Albert Einstein College of Medicine, NY), and have a reliance agreement with NEALS (Northeast ALS Consortium) and Massachusetts General, Boston, MA to assist in fast tracking phase 2 clinical trials that are part of NEALS (similar to NeuroNEXT), including the ongoing Amylyx pharmaceuticals Centaur study.
We are currently completing a phase 3 Orien pharmaceutical study of Levosimendan in the treatment of ALS.
We are participating in the ALS arm of the Mount Sinai Hospital’s NeuroNEXT grant.
We also studying ocular motor dysfunction in patients with ALS and other forms of motor neuron disease.
We are participating in NIH consortium grants studying Agrin and LRP for antibodies in double negative myasthenia gravis.
I offer telemedicine appointments when appropriate. Please call my office to schedule a video visit.
Dr. Scelsa is registered to provide telehealth services in Florida.
Am Board of Electrodiagnostic Medicine
Neurology, American Board of Psychiatry and Neurology
- Amyotrophic Lateral Sclerosis
- Bell's Palsy
- Carpal Tunnel Syndrome
- Chronic Inflammatory Demyelinating Neuropathy
- Diabetic Neuropathy
- Electrodiagnostic Testing (EMG/NCS)
- Electromyography (EMG)
- Guillain-Barré Syndrome
- Lumbar Radiculopathy
- Myasthenia Gravis
- Nerve conduction study (NCS)
- Neuromuscular Disease
- Neuropsychological testing
- Peripheral Neuropathy
Amyotrophic Lateral Sclerosis
MD, S.U.N.Y., Health Science Center
Internship, Internal Medicine
Montefiore Medical Center
Albert Einstein College of Medicine
Albert Einstein College of Medicine
EnglishDownload the CV
Pasik Teaching Award for Neurology Teaching
Mount Sinai Health System
Beth Israel Neurology Teaching Award
Beth Israel Neurology Teaching Award
M.D. conferred Cum Laude
Alpha Omega Alpha
B.S. conferred Summa Cum Laude
Chemistry Honor Society
Phi Beta Kappa
Nutritional Requirements in Amyotrophic Lateral Sclerosis
I had the benefit of contributing to nutrition-focused ALS research, mostly investigating the nutritional requirements and dietary interventions of ALS. One of the major nutrition in ALS initiatives I have been involved in was the ALS Nutrition/NIPPV Study Group. The results of this collaborative study allowed us to model equations to predict the energy requirements in ALS and to plan a study of early intervention with NIPPV. I have also contributed to what is known about 25-hydroxyvitamin D in ALS, showing that vitamin D supplementation may have a beneficial effect on ALSFRS-R scores.
Comorbidities and Amyotrophic Lateral Sclerosis
A large portion of my research has focused on ALS patients who present a comorbid disease; particularly HIV, dyspnea-fasciculation syndrome and progressive bulbar palsy. In regards to ALS and HIV, my research has documented the first time a patient with motor neuron disease and HIV infections has responded to antiviral therapy. My research has also described the dyspnea-fasciculation syndrome, the early presence of respiratory failure in ALS since concurrent chronic obstructive pulmonary disease augments the effect of ALS.
Amyotrophic Lateral Sclerosis Treatment Methods and Efficacy
I have been able to focus much of my research on the development and implementation of novel drug therapies for ALS through various randomized clinical trials. Using a novel phase II trial design, my collaborative research has assessed two drug combinations in ALS, providing a new effective trial design for future studies to assess different agents.
Genetics in Amyotrophic Lateral Sclerosis
I am proud to be a contributor of a large collaboration among academic investigators, government, and non-government organizations which has created a public repository of human DNA, immortalized cell lines, and clinical data to further gene discovery in ALS. This resource currently maintains samples and associated phenotypic data from 2332 MND subjects and 4692 controls. This resource should facilitate genetic discoveries which we anticipate will ultimately provide a better understanding of the biological mechanisms of neurodegeneration in ALS. I have personally been involved in DNA research of ALS, contributing to the role and pathologic basis of IgA gammopathy in the surviving motor neurons of ALS patients.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Scelsa during 2020 and/or 2021. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
- Aaronson Rappaport Feinstein & Deutsch, LLP
- DanaherLagnese PC
- Dorf, Nelson
- MCIC Vermont, Inc.
- Martin Clearwater & Bell LLP
- Physicians' Reciprocal Insurers (PRI)
- Shaub, Ahmuty, Citrin & Spratt, LLP
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.